Recently, Ali Health announced the mid-year report for the year ending September 30, 2016. The report showed that the current revenue was 55.02 million, up 220% from 17.19 million in the same period of last year. The loss before tax was 104 million, up slightly from 1.03 in the same period last year. Subdivided into specific business segments, the electronic supervision network is its main source of business, with current revenue of 48.983 million yuan, accounting for 89% of total revenue, and outsourcing and value-added service revenues provided to Tmall entities of 3.07 million, B2C pharmaceutical business 138 Wan, the importance of the electronic regulatory network in its business sector is evident.

The drug monitor code is transformed into a "code on the heart"

According to the information provided by Ali Health, after the State Food and Drug Administration issued the “Opinions on Further Improving the Food and Drug Traceability System (Draft for Comment), the pharmaceutical electronic supervision code system undertaken by Hebei Huiyan Pharmaceutical, a subsidiary of Ali Health, was Stopping, Ali Health decided to build an open, market-oriented third-party traceability platform, continue to use its experience and technical capabilities in the field of traceability system construction, with regulatory authorities, pharmaceutical companies, industry organizations, third-party technology service providers, and the public. Together, build a retrospective ecosystem of anti-counterfeiting drugs.

Ali Health said that the new platform will be fully compatible with the technical standards of the "China Drug Electronic Supervision Code", and will provide free services to medical institutions and pharmaceutical companies on the former China Drug Electronic Regulatory Network. In addition, in the next three years, Ali Health will not charge the fee for the basic traceability services such as sending code and flow inquiry to the settled enterprises, and will only charge technical support fees such as data storage and interface call.

Ali Pei, vice president of Ali Health, said that on the basis of ensuring the technical support cost of the new traceability platform, Ali Health will continue to increase its technical input and gradually implement technical indicators such as code standards, interface openness and platform security. Upgrade to make the platform run cheaper, more scalable, and more feature-rich. Ali Health has demonstrated strong technical strength in the operation and maintenance of the drug electronic supervision network. According to the report, in 2015, after the reconstruction and optimization of the Ali Health Technology Architecture, the electronic data of the drug regulatory network increased. Nearly four times, but the system processing speed is increased by twenty times, greatly improving efficiency and reducing costs.

In mid-June, Ali Health launched the “code-safe” tracking platform, which is compatible with the technical standards of “China Drug Electronic Supervision Code”, and provides free services to medical institutions and pharmaceutical companies on the former China Drug Electronic Regulatory Network. For dealers, the code is assured that it can assist dealers to record or identify the products they purchase, grasp the source of their products and the direction of sales, meet the national and local regulatory requirements, and help enterprises to fine-tune management.

According to the reporter's understanding, there are currently hundreds of pharmaceutical manufacturers that have settled on the platform. On August 18th, Panlong Yunhai signed an agreement with Ali Health, and its “Sanqi Powder” settled on the platform. Users can use Ali's shopping and pay APP scan code to view product origin, sales and flow information; September 26 Ma Yinglong also announced that he will be assured that the products will be on the platform and that all kinds of drugs will be marked with traceability codes to verify the authenticity of the products.

In conjunction with the news signed by Ali Health and the brand pharmaceutical company, its mid-year report has finally been released, with 48.98 million, which can be regarded as the first “transcript” of the Ali Health Product Traceability System after the drug monitor code was stopped. The results show both the layout of Ali Health in the traceability of medicines and the degree of recognition of the system by pharmaceutical companies.

Influenza Vaccine in Final Bulk

As a well-known, trustworthy and listed biotechnology company in China, Changchun BCHT Biotechnology Co. ([BCHT") has dedicated to biotechnology for over a decade and grown by leaps and bumps. And we hereby proudly introduce our products as below:

Influenza Vaccine, Live, Nasal, Freeze-dried (exclusively authorized by the WHO in China, for 3-17 years old, no injection and no pain)

The vaccine is inoculated by nasal spray, equipped with nasal spray device, and only needs to spray once a year in two nostrils to prevent influenza.

Mucosal immunity + Cellular immunity + Humoral immunity

Vaccination of Influenza Vaccine, Live, Nasal, Freeze-dried can quickly stimulate the triple immune response of human body, and carry out defense against viruses in different parts:

·Intranasal administration can produce mucosal immunity (IgA antibody), which forms the first immune defense line in the nasal cavity.

·Produce humoral immunity (IgG antibody) to remove influenza virus from body fluids.

·Produce cellular immunity (T cells) to remove influenza virus from cells

Changchun BCHT Biotechnology Co.`s Influenza Vaccines can also be manufactured in final bulk form.

Look forward to your early reply.

Changchun BCHT Biotechnology Co. , https://www.ccbcht.net